Article Details

6-Year Data Support Long-Term Safety of Upadacitinib - Dermatology Times

Retrieved on: 2025-09-20 21:14:20

Tags for this article:

Click the tags to see associated articles and topics

6-Year Data Support Long-Term Safety of Upadacitinib - Dermatology Times. View article details on hiswai:

Excerpt

Following treatment with remibrutinib, CUI+ patients demonstrated significant reductions in FcεRI- and TG-specific IgG levels compared with placebo at ...

Article found on: www.dermatologytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo